Patent application EP16175032A (EP), filed 2016-06-17
Publication number: EP3257502A1
Title: FORMULATIONS IN THE FORM OF CAPSULES FOR ORAL SYSTEMIC ADMINISTRATION COMPRISING S-ADENOSYLMETHIONINE AND POLYUNSATURATED FATTY ACIDS, PREPARATION AND USE THEREOF
Abstract: There are described formulations in the form of capsules for oral systemic administration comprising S-adenosylmethionine or salts thereof as an active ingredient, wherein said active ingredient is dispersed in a lipid carrier selected from: omega-3 or omega-6 fatty acids.
IPC codes: A61K  31/  7076            A I
A61K  45/    06            A I
A61K   9/    48            A I
A61K   9/    52            A I
A61P   1/    16            A I
A61P  25/    02            A I
A61P  25/    24            A I
A61P  27/    02            A I
A61P   9/    00            A I
Claims: number: 1
text: Formulations in the form of capsules comprising SAMe or salts thereof as active ingredient, and bivalent or monovalent metal salts or mixtures thereof as excipients, wherein said active ingredient is dispersed in a lipid carrier selected from: omega-3 or omega-6 fatty acids.
number: 2
text: Formulations according to claim 1, wherein the excipient is magnesium sulfate.
number: 3
text: Formulations according to claims 1 and 2, wherein the active ingredient is 25-65% by weight, the active lipid carrier is present up to 70% by weight, and the excipients are present up to 15% by weight, wherein said percentages are calculated on the total content of the capsule.
number: 4
text: Formulations according to claims 1-3, further containing: antioxidants, vitamins, inositol, 5-HTP, amino acids, folic acid and folate, minerals, such as selenium, zinc, magnesium, copper, iodine, either in the form of salt or in the form of liposomes or complexes.
number: 5
text: Formulations according to claims 1-4, in the form of hard or soft capsules.
number: 6
text: A process for preparing capsules according to claims 1-5, wherein:
number: 7
text: Capsules according to claims 1-5 for use in the treatment of depression, liver diseases, inflammatory diseases and peripheral (diabetic and non-diabetic) neuropathies, and microvascular retinal disorders.
Office action: search_report, dated 2017-12-20
Rejection reasons: novelty_epc_54
Prior art cited: ref_id: US2002164369A1
ref_type: patent
severity: background
ref_id: GB2064523A
ref_type: patent
severity: background
ref_id: WO2009076353A1
ref_type: patent
severity: background
ref_id: US2002164369
ref_type: patent
severity: novelty_destroying
ref_id: GB2064523
ref_type: patent
severity: background
ref_id: WO2009076353
ref_type: patent
severity: background
Final disposition: pending (2017-12-20)